Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 10730927
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 4, 2020
    Assignee: CSL LIMITED
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Patent number: 10722531
    Abstract: Improved methods for treating cancer are provided herein by determining if a cancer patient, particularly a colon cancer patient or a gastric cancer patient, will clinically respond in a favorable manner to a therapeutic strategy comprising the FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin) or a combination of capecitabine and cisplatin. Diagnostic methods for measuring the OPRT, TYMP, and/or UCK2 proteins in a tissue sample, such as a tumor sample, from the patient are provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Patent number: 10725045
    Abstract: Methods are provided for treating a cancer patient suffering from a glioblastoma (GBM) by administering to the patient an effective amount of temozolomide, wherein a mass spectrometry analysis of a protein digest of a formalin-fixed tumor sample from the patient evidences an amount of a MGMT fragment peptide less than or substantially equal to 150 amol/?g.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Patent number: 10722509
    Abstract: Methods are provided herein for identifying whether a cancer patient, for example a colorectal cancer patient, will be responsive to treatment with a therapeutic strategy comprising administration of the FOLFOX regimen (5-fluorouracil, leucovorin, and oxaliplatin). Specified TYMP and UCK2 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, for example colorectal cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the combination treatment of FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin).
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Fabiola Cecchi, Todd Hembrough
  • Patent number: 10718780
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the tyrosine-protein kinase receptor UFO protein (AXL) that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 21, 2020
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Todd Hembrough, Adele Blackler, Wei-Li Liao
  • Patent number: 10718779
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: July 21, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Patent number: 10712348
    Abstract: Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 14, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Cory E. Bystrom, Richard E. Reitz
  • Patent number: 10709757
    Abstract: The present invention relates to a composition for inhibiting angiogenesis, containing neo-N-methylsansalvamide (NMSSV), which is a cyclic pentadepsipeptide, as an effective ingredient, and specifically, since the NMSSV of the present invention has excellent activity which inhibits cell migration and tube formation associated with angiogenesis, and concentration-dependently inhibits angiogenesis induced by a vascular endothelial growth factor, it is expected that the NMSSV of the present invention may inhibit angiogenesis and be usefully used as a therapeutic agent for various diseases in which angiogenesis is abnormally regulated.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: July 14, 2020
    Assignee: CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Chan Lee, Sung-Kwon Moon, Jee Taek Kim
  • Patent number: 10711039
    Abstract: Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 14, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 10702522
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: July 7, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • Patent number: 10702573
    Abstract: The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: July 7, 2020
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Balasingam Radhakrishnan, Kenneth Duke James, Jr., Anuradha Vaidya, Karen Polowy
  • Patent number: 10702606
    Abstract: The present invention provides a peptide composition that can achieve both excellent storage stability and transparency. The peptide composition of the present invention includes: a self-assembling peptide; a buffering agent having a pKa of 3.5 or more and less than 7.5 and containing one or more nitrogen atoms; and water, and has a pH of from 4.5 to 6.6.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: July 7, 2020
    Assignee: MENICON CO., LTD.
    Inventors: Yuya Suganuma, Tatsuya Ojio, Hidenori Yokoi
  • Patent number: 10702579
    Abstract: Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided. In another exemplary embodiment of the present disclosure, a composition containing an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided. In a related exemplary embodiment of the present disclosure, a method for lowering or reducing cholesterol levels in an individual is provided where a product containing an effective amount of lunasin peptides to an individual is provided and a claim that the product lowers or reduces cholesterol, total cholesterol, LDL cholesterol or lipid levels in an individual that consumes the composition is made.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: July 7, 2020
    Assignee: SL Technology, Inc.
    Inventor: Alfredo Flores Galvez
  • Patent number: 10695395
    Abstract: The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 30, 2020
    Assignee: PHOENIX TISSUE REPAIR, INC.
    Inventors: Igor Quinones-Garcia, Lin Guey, Kris Lowe, Vinh Nguyen, Bing He, Amey Bandekar, Sujit Basu
  • Patent number: 10694739
    Abstract: The present invention provides peptoid polymers capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids comprising the peptoid polymers provided herein. The peptoid polymers and peptoid-peptide hybrids provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: June 30, 2020
    Assignee: X-THERMA, INC.
    Inventor: Xiaoxi Wei
  • Patent number: 10697971
    Abstract: The present invention relates to a diagnosis method of liver cancer using mass spectrometry of ?-fetoprotein derived glycopeptide. Particularly, according to the AFP glycopeptide analysis method of the invention, fucosylation rate of the glycopeptide having the sequence composed of Val-Asn-Phe-Thr-Glu-Ile-Gln-Lys is analyzed to diagnose liver cancer in the early developmental grade. In particular, fucosylation rate is higher in the liver cancer patients than in other liver disease patients, so that the comparison of the fucosylation rate can be useful to diagnose or distinguish liver cancer from other liver diseases in the early HCC patients.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 30, 2020
    Assignee: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Jong Shin Yoo, Kwang Hoe Kim, Jin Young Kim, Ju Yeon Lee
  • Patent number: 10695402
    Abstract: This invention relates to treating gastrointestinal dysfunction with erythropoietin (EPO) or its analog.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 30, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: John Elfar, Walaa Elfar, Mark Noble
  • Patent number: 10689430
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 23, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
  • Patent number: 10683326
    Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 16, 2020
    Assignee: Stealth BioTherapeutics Corp.
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Patent number: 10670606
    Abstract: The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partne
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 2, 2020
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Albrecht Moritz, John Edward Rush, II, Roberto Polakiewicz